At a high level, people who received risk mitigation dispensations, particularly opioids, in the week after receipt had a much lower risk of death. We saw a biological gradient in that effect. More dispensations led to a lower risk of death. That was controlling for access to OAT, so it was independent of access to OAT.
We've since come up with a separate study looking at coprescription, because doctors often coprescribe hydromorphone tablets alongside OAT. We actually saw some really positive benefits in terms of improving retention in treatment.